Genentech’s Itovebi Demonstrates Survival Benefit in HR-Positive Advanced Breast Cancer
Genentech Announces Positive OS Results for Itovebi in Advanced HR-Positive Breast Cancer Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), has announced positive topline results from…
Cannabis Pharmaceuticals Market 2024-2034: Focus on Sativex, Cesamet, Marinol, Epidiolex – ResearchAndMarkets.com
Cannabis Pharmaceuticals Market 2024-2034: Focus on Sativex, Cesamet, Marinol, Epidiolex – ResearchAndMarkets.com The global cannabis pharmaceuticals market, valued at USD 3.46 billion in 2023, is expected to experience remarkable growth,…
ENHERTU® Approved in U.S. for HER2-Low Metastatic Breast Cancer Post-Endocrine Therapy
ENHERTU® Approved in U.S. for HER2-Low Metastatic Breast Cancer Post-Endocrine Therapy Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment…
Ncardia Launches Ncyte® Heart in a Box for Precision Cardiovascular Research – Release 1
Ncardia, a global leader in human induced pluripotent stem cell (hiPSC) technology, has officially launched the Ncyte® Heart in a Box, an innovative 3D model of cardiac microtissue designed to…
Arcus Biosciences Names Richard Markus, M.D., Ph.D. as Chief Medical Officer
Arcus Biosciences Appoints Richard Markus, M.D., Ph.D., as Chief Medical Officer Arcus Bioscience a clinical-stage biopharmaceutical Officer company focused on developing novel molecules and combination therapies for cancer treatment, has…
Salubris Biotherapeutics Reports Positive Interim Data from Phase 2 Heart Failure Trial of JK07
Salubris Biotherapeutics Announces Positive Interim Data from Phase 2 Trial of JK07 in Heart Failure Salubris Biotherapeutics a clinical-stage biotechnology company focused on developing innovative biologic therapies, has announced promising…
Roche Gets FDA Clearance for CLIA-Waived STI Point-of-Care Tests
Roche Receives FDA Clearance for CLIA-Waived STI Point-of-Care Tests Roche has announced a major milestone in the realm of sexual health diagnostics. The U.S. Food and Drug Administration (FDA) has…
Sarclisa Approved in EU for Treating Transplant-Ineligible Newly Diagnosed Multiple Myeloma
European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the EU has approved Sarclisa in combination with a standard-of-care regimen—bortezomib, lenalidomide, and dexamethasone (VRd)—for the treatment of…
Phase 2 Trial: Cytokinetics Launches AMBER-HFpEF Study of CK-586 in Symptomatic HFpEF
Introduction: Cytokinetics Advances CK-586 into Phase 2 Trial Cytokinetics, Incorporated a leading biopharmaceutical company, has announced that enrollment is now open for AMBER-HFpEF, a pivotal Phase 2 clinical trial evaluating…
BrainChild Bio Receives Prestigious G-Rex® Grant from ScaleReady
BrainChild Bio Receives Recognition for Innovation in Cell Therapy ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, has announced that BrainChild Bio has been awarded a $300,000…
WHO Responds to U.S. Announcement of Withdrawal Intent
WHO Expresses Regret Over U.S. Withdrawal Announcement The World Health Organization (WHO) has expressed deep regret over the announcement that the United States intends to withdraw from the Organization. The…
Poxel to Gain Increased Royalties from Sumitomo Pharma for TWYMEEG Sales in Japan
Poxel Achieves Milestone with TWYMEEG® Sales in Japan, Secures Royalties and Sales-Based Payments Poxel, a clinical-stage biopharmaceutical company focused on innovative treatments for chronic serious diseases with metabolic pathophysiology—including metabolic…